Matthew W. Johnson, Ph.D., is an expert on psychoactive drugs and addiction. For 15 years he has conducted psychedelic research. He has published >100 manuscripts, with 42 focused on psychedelics. Matt published psychedelic administration safety guidelines in 2008, the first research investigating psychedelic treatment of tobacco/nicotine addiction in 2014, and the largest study of psilocybin in treating cancer distress in 2016. His recent review of psilocybin abuse liability recommended its placement in Schedule IV upon medical approval. He has guided >100 psychedelic sessions. Matt has been interviewed by the BBC, New York Times, Washington Post, CNN, and Wall Street Journal.